# Presentation: 218801

## FDA/CDRHOffice of In Vitro Diagnostic Devices   The Pre-IDE ProcessSousan S. Altaie, Ph.D.Scientific Policy Advisor510(k) workshop, April 18-19, 2006 

**OIVD**

## The #1 factor impacting review timeliness isQuality of the Submission

**OIVD**

## An Overview 

- Introduction
- Pre-IDE Process
- Protocol proposal by sponsor
- Review by FDA review team
- Meeting with sponsor
- Written feed back to sponsor
- Summary
- Question and answer period

**OIVD**

## Introduction

- What is a Pre-IDE?
- A misnomer
- A free consultative service by the review staff at  the FDA
- A non binding agreement between FDA & sponsor
- Results in a well prepared submission
- Results in a  shortened review time
- Results in saving research $$$

**OIVD**

## Pre-IDE Process

**OIVD**

## Protocol proposal (1)

- Introduction
- A clearly stated intended use
- Test principles
- Device description

**OIVD**

## Intended Use Statement

- Should address the followings:
- Qualitative or Quantitative
- Testing matrix
- Intended Population
- Adult /Children/Age limitations
- Asymptomatic--Screening
- Symptomatic--Diagnosis
- Already diagnosed--Monitoring
- In conjunction with other diagnostics or stand alone test

**OIVD**

## Protocol proposal (2)

- Objectives of the clinical Study
- To substantiate the proposed intended use
- To establish the assay performance characteristics

**OIVD**

## Protocol proposal (3)

- Study Design--points to consider
- A controlled comparative study to establish clinical performance of device compared to an established endpoint or surrogate
- Clearly show how endpoints are defined
- Patient  samples should have inclusion and exclusion criteria

**OIVD**

## Study Design (continued)

- The number of patients/samples to be enrolled/used should be determined on sound statistical parameters
- Provide protocols for patient/sample information collection and documentation
- How and by whom
- Consider having _>_ 3 clinical sites
- provide contact information for all the PIs

**OIVD**

## Protocol proposal (4)

- Laboratory testing Procedures
- Clinical labs performing the testing during clinical trial Should follow the procedure in the proposed product insert for both the comparetor and the test device
- Specimen type should be defined
- specimen collection, transport, process, and storage Should be defined
- Quality control for the assay should be defined
- frequency and trouble shooting

**OIVD**

## Protocol proposal (5)

- Study results
- How results are reported to sponsor
- How results are analyzed
- Describe statistical tests
- Describe how discrepant results are handled
- Definition of true positive, true negative, equivocal, and inconclusive results for the purpose of establishing performance of the device

**OIVD**

## Protocol proposal (6)

- Regulatory & Administrative information
- Study’s start and finish dates
- Obligations of the PI and sponsor
- IRB & informed consent (non-US, Helsinki Accord)
- Study site monitoring
- SOPes for protocol deviation & change

**OIVD**

## Protocol review by FDA 

- Review Team
- Division team leader
- Division review staff
- Internal and external Consultant
- CDER, CBER, CDRH, CVM, CFSAN, CDC, NIH...
- Internal FDA discussions
- Creation of consensus

**OIVD**

## Meeting with sponsor

- Face to Face
- Teleconference
- Videoconference

**OIVD**

## Written feed back 

- E-mail
- Fax
- Mail

**OIVD**

## Summary

- The pre-IDE is
- the current agency’s thinking
- extremely flexible framework for product development
- does not bind the FDA or the sponsor
- A streamlined method in which the FDA and the sponsor can agree on criteria and data necessary to insure safety and efficacy of  device prior to start of  preclinical and clinical trials → $$$$

**OIVD**

## Real-life Example

- Same device type
- Same branch
- Same reviewer
- Same timeframe
- different quality

**OIVD**

## Another Example

- Same as previous slide
- Quality Submission
- Right Studies
- Sponsor improvement

**OIVD**

## OIVD

**OIVD**

**Notes:**
And they interconnect.  They interconnect because all parts of the cycle inform and are pathways to other parts.  They interconnect because products further along in the cycle inform and affect new products earlier in the cycle.  They interconnect because a safe and effective device or radiological health product can’t be developed without some knowledge of all the parts.

## OIVD

**OIVD**